araag2/HINT huggingface dataset:
Clinical trial NCT00409292 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: rad001
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Pathologic confirmation of pancreatic adenocarcinoma

          -  18 years of age or older

          -  At least one measurable site of disease according to RECIST criteria that has not been
             previously irradiated. If patient has had previous radiation to the marker lesion(s),
             there must be evidence of progression since the radiation.

          -  Treated with gemcitabine-based chemotherapy with documented tumor progression on
             gemcitabine or intolerance to gemcitabine.

          -  Prior treatment with no more than 1 prior chemotherapy regimen for metastatic disease.

          -  Minimum of two weeks since any major surgery, completion of radiation, or completion
             of all prior systemic anti-cancer therapy.

          -  ECOG performance status 0-1.

          -  Life expectancy of greater than 12 weeks.

          -  Adequate bone marrow and liver function.

          -  Must be able to swallow tablets.

        Exclusion Criteria:

          -  Prior treatment with an investigational drug within the preceding 4 weeks.

          -  Prior treatment with an inhibitor of mTOR

          -  Chronic treatment with systemic steroids or another immunosuppressive agent

          -  More than one prior chemotherapy treatment for metastatic disease

          -  Uncontrolled brain or leptomeningeal metastases, including patient who continue to
             require glucocorticoids for brain or leptomeningeal metastases.

          -  Other malignancies within the past 3 years except for adequately treated carcinoma of
             the cervix or basal or squamous cell carcinomas of the skin

          -  Patients with chronic renal insufficiency

          -  Other concurrent severe and/or uncontrolled medical disease which could compromise
             participation in the study.

          -  Known history of HIV seropositivity

          -  Impairment of gastrointestinal function or gastrointestinal disease that my
             significantly alter the absorption of RAD001.

          -  Active, bleeding diathesis or an oral vitamin K antagonist medication

          -  Women who are pregnant or breast feeding
Clinical trial NCT00338130 (phase 2, status: completed)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: azd6244, temozolomide
SMILES: CN1C=NC2=C1C=C(C(O)=NOCCO)C(NC1=C(Cl)C=C(Br)C=C1)=C2F, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with late stage malignant melanoma

          -  Aged 18 or over

          -  Female patients must be post-menopausal or with negative urine pregnancy test if
             pre-menopausal

        Exclusion Criteria:

          -  Any previous radiotherapy or chemotherapy (palliative radiotherapy is acceptable)

          -  Participation in any other trial with an investigational product within the previous
             30 days
Clinical trial NCT00210795 (phase 2, status: terminated)
Conditions: anemia, aged, hemoglobins
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: epoetin alfa
SMILES: OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O
Reason stopped: 
    this study was stopped due to slow enrollment after enrolling only 12 of 80 patients over 14
    months time.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with a history of chronic anemia defined as a documented Hb value of <= 11.0
             g/dL

          -  No active cancer

          -  At least 65 years of age with life expectancy of > 6 months

          -  Community dwelling patients

          -  Patients with a Short Physical Performance (SPPB) Summary Score of 4-10 at screening
             and baseline

          -  Patients with an Mini Mental State Examination (MMSE) score >= 24

        Exclusion Criteria:

          -  Positive stool guaiac test

          -  Diagnosis of multiple myeloma and/or MGUS

          -  History of venous thromboembolytic disease

          -  Previous treatment with Epoetin alfa, Darbepoetin or any form of erythropoietin
             recently

          -  Uncontrolled or severe cardiovascular disease
Clinical trial NCT00014313 (phase 2, status: terminated)
Conditions: sarcoma
ICD codes: C96.A, C46.9, C96.22, C46.0, C46.2, C92.31, C92.32
Drugs: cisplatin, etoposide
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed Ewing's family tumor as characterized by the following:

               -  Positive MIC2 on immunohistochemistry OR

               -  Evidence of a chromosomal translocation involving the EWS gene by conventional
                  cytogenetics

                    -  t(11; 22) translocation or variant OR

                    -  Demonstration of EWS/FLI1 or EWS/ERG gene fusion by PCR or FISH

          -  Metastases outside the lung or pleura

          -  At least 1 measurable lesion outside of previously irradiated area

          -  No symptomatic or known CNS metastases

        PATIENT CHARACTERISTICS:

        Age:

          -  15 to 65

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm3

          -  Neutrophil count at least 2,000/mm3

          -  Platelet count at least 100,000/mm3

        Hepatic:

          -  Bilirubin less than 3 mg/dL

          -  Albumin greater than 2.5 g/dL

        Renal:

          -  Creatinine less than 1.2 mg/dL

          -  Creatinine clearance greater than 70 mL/min

        Cardiovascular:

          -  No history of uncontrolled cardiovascular disease

        Other:

          -  No other severe medical illness, including psychosis

          -  No other prior primary malignancy except adequately treated carcinoma in situ of the
             cervix or basal cell skin cancer

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  See Disease Characteristics

        Surgery:

          -  Not specified
Clinical trial NCT00270790 (phase 2, status: completed)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: amifostine, carboplatin, taxol
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Eligibility criteria:

        Inclusion Criteria:

          1. Histologically proved locally advanced squamous cell carcinoma of the head and neck of
             all primary sites. The following TNM stages by sites will be eligible.

             Oral cavity, Pharynx, Larynx, Nasopharynx, paranasal sinuses: T4 N0-3, A,B,C T3 N1-3
             A,B,C any T, N3 A,B,C Unknown primary: Tx, N3 A,B,C Note: Only clearly unresectable T4
             N0 lesions are eligible for study provided the reasons for unresectability are due to
             extensive anatomic involvement and are outlined by the surgeon.

          2. Karnofsky performance status of 70% or better at screen and on first day of treatment.

          3. Patients with loco-regional recurrences from any site with no prior radiation therapy
             and not amenable for salvage surgery are eligible for study.

          4. No evidence of distant metastatic disease.

          5. No previous radiation therapy

          6. No previous chemotherapy.

          7. Adequate renal & bone marrow function determined by the following laboratory
             parameters.

             WBC 3500/ul or higher Platelet count 100.000/ul or higher Hemoglobin 9.0 g/dl or
             higher BUN 25 mg/dl or less, and Screatinine 2.0 mg/dl or less Total bilirubin less
             than 2.0 mg/dl, AST/ALT less than 3 times the ULN Creatinine Clearance 50 cc/min or
             higher

          8. Evidence of measurable disease.

          9. No evidence of concomitant malignancy except for non-melanomatous skin cancer
             (controlled or controllable) or carcinoma in situ of the cervix.

         10. Signed informed consent.

         11. No concomitant life threatening or uncontrolled serious medical illness such as end
             stage congestive heart failure cardiac arrythmia, liver disease and organic brain
             syndrome.

         12. Age 18 years or older.

        Exclusion Criteria:

          1. Preexisting clinically significant neuropathy.

          2. Patients currently taking antiarrhythmic medications are excluded.

          3. History of poorly-controlled hypertension, angina, arrhythmias, or a history within
             the past 6 months of myocardial infarction or acute congestive heart failure.

          4. Requirement for concurrent use of pilocarpine.

          5. Treatment with any investigational drugs within 4 weeks of study entry.

          6. Pregnant or lactating females or females of child bearing potential not employing
             adequate contraception.
Clinical trial NCT00698022 (phase 2, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: risperidone, risperidone matched placebo, risperidone-matched placebo, mifepristone-matched placebo
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  BMI ≥ 18 and ≤ 23 kg/m2

          -  Able to provide written informed consent

          -  Routine clinical laboratory tests either within normal limits or not clinically
             meaningful if outside of normal limits

          -  AST, ALT, Tbili within normal limits at screening

          -  Medical and psychiatric history and physical examination devoid of any significant
             findings that would interfere with participation or interpretation of results in this
             study

          -  Agree to use a barrier method of birth control for 28 days following the last dose of
             study medication

          -  Have maintained a stable weight for at least 6 months prior to Screening

        Exclusion Criteria:

          -  Prior or current history of any psychiatric disorder, including eating disorders such
             as anorexia nervosa, bulimia nervosa, or binge-eating disorder

          -  Positive urine drug screen for any drug of abuse (including amphetamines,
             cannabinoids, barbiturates, cocaine, opiates, benzodiazepines) unless prescribed by a
             physician

          -  Participation in a clinical investigation of any drug, biological or other
             investigational therapy within 30 days prior to dosing

          -  Have a history of an allergic reaction to either mifepristone or risperidone

          -  Any other clinically significant abnormality on screening laboratory tests

          -  QTc Bazzett's ≥ 450 msec

          -  History of or current major medical condition, which in the opinion of the
             Investigator would place the patient at undue risk.

          -  Receiving any prescription or over-the-counter medications that could potentially
             affect appetite or weight

          -  Any history of a movement disorder such as Tardive Dyskinesia, Parkinsonism

          -  Any personal or family history of Neuroleptic Malignant Syndrome
Clinical trial NCT00246571 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: su011248, chemotherapy
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Recurrent or metastatic breast cancer

          -  Estrogen receptor (ER), progestin receptor (PR) and HER2/neu receptor (HER2) negative
             status

          -  Prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease
             setting

          -  Relapse following adjuvant chemotherapy within 6 months of last treatment and/or
             received one or two chemotherapy regimens for advanced disease

        Exclusion Criteria:

          -  More than two chemotherapy regimens for advanced disease

          -  Uncontrolled/symptomatic spread of cancer to the brain
Clinical trial NCT01095120 (phase 2, status: unknown status)
Conditions: adenocarcinoma of the stomach, adenocarcinoma of esophagogastric junction
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: tesetaxel
SMILES: CN(C)C[C@@H]1O[C@H]2[C@@H](O1)[C@]1(C)CC[C@H]3OC[C@@]3(OC(C)=O)[C@H]1[C@H](OC(=O)C1=CC=CC=C1)[C@]1(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C3=C(F)C=CC=N3)C(C)=C2C1(C)C
Eligibility criteria:

        Primary inclusion criteria:

          -  Confirmed diagnosis of adenocarcinoma of the stomach or esophagogastric junction

          -  Measurable disease (revised RECIST; Version 1.1) based on computed tomography

          -  Eastern Cooperative Oncology Group performance status 0 or 1

          -  Treatment with only 1 prior regimen (as first-line therapy) and that regimen included
             a fluoropyrimidine and/or a platinum analogue

          -  Documented disease progression within 4 months of the last dose of the 1 prior regimen

          -  Adequate bone marrow, hepatic, and renal function, as defined in the protocol

          -  At least 4 weeks and recovery from effects of prior surgery or other therapy,
             including immunotherapy, radiation therapy, or cytokine, biologic or vaccine therapy,
             with an approved or investigational agent

          -  Ability to swallow an oral solid-dosage form of medication

        Primary exclusion criteria:

          -  Nonmeasurable disease only (revised RECIST; Version 1.1)

          -  History or presence of brain metastasis or leptomeningeal disease

          -  Operable gastric cancer or operable cancer of the esophagogastric junction

          -  Uncontrolled diarrhea, defined as more than 3 loose bowel movements above the
             patient's usual number of bowel movements on at least 2 days within the 14 days prior
             to enrollment

          -  Uncontrolled nausea or vomiting within the 14 days prior to enrollment despite the
             administration of standard antiemetic therapy

          -  Known malabsorptive disorder

          -  Significant medical disease other than cancer, as defined in the protocol

          -  Presence of neuropathy > Grade 1 (National Cancer Institute Common Toxicity Criteria
             [NCI CTC]; Version 4.0)

          -  Prior treatment with a taxane or other tubulin-targeted agent (eg, indibulin) other
             than a vinca alkaloid

          -  Need to continue any regularly-taken medication that is a potent inhibitor or inducer
             of the CYP3A pathway or P-glycoprotein activity
Clinical trial NCT00482950 (phase 2, status: unknown status)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: phx1149t
SMILES: OB(O)[C@@H]1CCCN1C(=O)CN[C@@H]1CCNC1
Eligibility criteria:

        Key Entry Criteria:

          -  Type 2 diabetes mellitus, diagnosed at least 4 months but not more than 12 years prior
             to screening.

          -  Male and non-pregnant, non-lactating (and not planning to become pregnant during the
             study) female subjects with a BMI of 25 to 48 kg/m2, inclusive. For India the BMI is
             23 to 48 kg/m2, inclusive.

          -  Current treatment of Type 2 diabetes mellitus with a stable dose of metformin of 1500
             mg or more (or the highest tolerated dose), or TZD (any labeled dose), or metformin +
             TZD at doses used in accordance with product labeling for at least 4 weeks (metformin)
             or 10 weeks (TZD) prior to screening (Visit 1).

          -  Fasting plasma glucose of 118 - 220 mg/dL (6.6 - 12.2 mmol/L), inclusive; HbA1c 7.3% -
             11.0%, inclusive; and a fasting plasma C peptide greater than 0.26 nmol/L at
             screening. For Argentina the allowed upper limit of HbA1c is ≤ 10.5%. For Canada the
             upper limit will be 10.0%

          -  No Type 1 diabetes mellitus or marked diabetic long-term complications.
Clinical trial NCT01020994 (phase 2, status: completed)
Conditions: eczema
ICD codes: B00.0, L20.82, L20.84, L20.83, H01.131, H01.132, H01.133
Drugs: las41003, las189962, las189961
SMILES: [H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Clinically diagnosed super-infected or impetiginized eczema

        Exclusion Criteria:

          -  Patients who have general signs of systemic infections like fever, malaise,
             lymphangitis or swollen lymph nodes and / or need systemic antibiotic treatment

          -  Patients who have a bacterial skin infection which, due to depth and severity, could
             not be appropriately treated with a topical antimicrobial or antiseptic medication

          -  Diagnose of the following disease:

               -  Known active tuberculosis or any history of past tuberculosis of skin

               -  Suspected or proven parasitic infection of the treatment site (e.g. scabies)

               -  Psoriasis

               -  Suspected or proven viral infection of skin (e.g. Herpes)

          -  Localization of the superficial infected eczema:

               -  Palms of the hands

               -  Sole of a foot

               -  Face

          -  Have received any topical treatment with antibiotics, antimycotics, immunomodulators
             and corticosteroid preparations within the last 2 weeks before treatment with IMP
Clinical trial NCT01257204 (phase 2, status: completed)
Conditions: hepatitis c virus
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: placebo, daclatasvir, pegylated interferon alfa-2a, ribavirin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C1=NC=C(N1)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CN=C(N1)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)OC)C(C)C, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Participants chronically infected with hepatitis C virus (HCV) genotype 2 or 3

          -  No previous exposure to an interferon formulation (ie, interferon alfa, pegylated
             interferon alfa-2a ) or ribavirin

          -  Body mass index (BMI) of 18 to 35 kg/m^2, inclusive. BMI=weight (kg)/height (m)^2

          -  Males and females, 18 - 70 years of age

        Key Exclusion Criteria:

          -  Liver transplant recipients

          -  Documented or suspected hepatocellular carcinoma

          -  Evidence of decompensated cirrhosis

          -  History of chronic hepatitis B virus (HBV). Patients with resolved HBV infection may
             participate

          -  Current or known history of cancer

          -  Any gastrointestinal disease or surgical procedure that may impact the absorption of
             study drug

          -  Inability to tolerate oral medication

          -  Poor venous access

          -  Severe psychiatric disease

          -  History of chronic pulmonary disease

          -  History of cardiomyopathy, coronary artery disease (including angina), interventive
             procedure for coronary artery disease (including angioplasty, stent procedure, or
             cardiac bypass surgery), ventricular arrhythmia,, or other clinically significant
             cardiac disease

          -  History of or current electrocardiogram findings indicative of cardiovascular
             instability

          -  Preexisting ophthalmologic disorders considered clinically significant on eye

          -  History of uncontrolled diabetes mellitus

          -  Any known contraindication to pegylated interferon alfa-2a or ribavirin not otherwise
             specified.

          -  Positive hepatitis B virus surface antigen, HIV-1 or HIV-2 Ab

          -  Prior exposure to any HCV direct antiviral agent (eg, HCV protease, polymerase,
             previous nonstructural protein 5A inhibitors)

          -  Exposure to any investigational drug or placebo
Clinical trial NCT01254565 (phase 2, status: completed)
Conditions: secondary hyperparathyroidism
ICD codes: E21.1, N25.81
Drugs: etelcalcetide, placebo
SMILES: C[C@@H](NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](CCCNC(N)=N)NC(=O)[C@@H](C)NC(=O)[C@@H](CSSC[C@H](N)C(O)=O)NC(C)=O)C(=O)N[C@H](CCCNC(N)=N)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject provides written informed consent.

          -  Intact parathyroid hormone (PTH) at least 350 pg/mL.

          -  Corrected calcium at least 9.0 mg/dL.

          -  Hemoglobin at least 9.0 g/dL.

          -  Adequate hemodialysis three times per week.

          -  Excepting chronic renal failure, subject is judged to be in stable medical condition
             based on medical history, physical examination, and routine laboratory tests.

        Exclusion Criteria:

          -  History or symptomatic ventricular dysrhythmias.

          -  History of angina pectoris or congestive heart failure

          -  History of myocardial infarction, coronary angioplasty, or coronary artery bypass
             grafting within the past 6 months.

          -  History of or treatment for seizure disorder.

          -  Recent (3 months) parathyroidectomy.

          -  Serum transaminases (alanine aminotransferase, aspartate aminotransferase) greater
             than two times the upper limit of normal at screening.
Clinical trial NCT00590590 (phase 2, status: completed)
Conditions: vulvodynia
ICD codes: N94.818, N94.819
Drugs: lidocaine/diphenhydramine, lidocaine, placebo
SMILES: CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1, OC1=CC(Cl)=CC=C1OC1=C(Cl)C=C(Cl)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have sought doctor's care for this condition.

          -  Patients must be having menstrual cycles.

        Exclusion Criteria:

          -  Patients must not have any vaginal infections.

          -  Patients must not be pregnant or nursing.

          -  Must not be receiving any other medicinal therapies or any medications that would
             interfere with the outcome of the study.